article thumbnail

A Whole Different Kind of Research Rodeo: ACRP Marks Five Years of Medical Device Certification

ACRP blog

Medical device trials, however, are typically smaller in scale and require fewer phases [than drug trials]. The information from this site goes on to describe how medical device studies are divided into three different classes, rather than into the familiar phases of drug studies.

article thumbnail

STAT+: Vaccine developer raises $45M for influenza drug trial

STAT News

Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association. Want to stay on top of the science and politics driving biotech today? 

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

Bio Pharma Dive

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

article thumbnail

Alnylam details anticipated results from heart disease drug trial

Bio Pharma Dive

Fuller data from Alnylam’s APOLLO-B trial confirm the success reported by the company last month, but won’t end a debate on the degree of benefit offered by its drug.

article thumbnail

Alnylam change to heart drug trial sparks doubts, sinking shares

Bio Pharma Dive

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

article thumbnail

EyePoint sees stock surge on AMD drug trial data

Bio Pharma Dive

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

article thumbnail

Amgen to test new way to lower heart risk with large drug trial

Bio Pharma Dive

Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).